Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration | Zendy

Hailing Xu | Zendy; Dongqing Lv | Zendy; Yinnan Meng | Zendy; Miao Wang | Zendy; Wei Wang | Zendy; Chao Zhou | Zendy; Suna Zhou | Zendy; Xiaofeng Chen | Zendy; Haihua Yang | Zendy

Open Access

Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration

Author(s) -

Hailing Xu,

Dongqing Lv,

Yinnan Meng,

Miao Wang,

Wei Wang,

Chao Zhou,

Suna Zhou,

Xiaofeng Chen,

Haihua Yang

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm.2020.01.16

Subject(s) - medicine , carboplatin , vinorelbine , chemoradiotherapy , lung cancer , oncology , radiation therapy , cetuximab , gastroenterology , chemotherapy , urology , cancer , cisplatin , colorectal cancer

The role of vascular targeting therapy combined with concurrent chemoradiotherapy (CRT) has produced many inconsistent results in locally advanced non-small-cell lung cancer (NSCLC), especially in lung squamous cell carcinoma (LSCC). Lipoprotein (a) [Lp(a)] may be critical in the development of tumor angiogenesis, and its levels are individualized and determined genetically. This study aimed to determine whether Lp(a) is correlated with effects of recombinant human endostatin (Endostar) combined with concurrent CRT for locally advanced LSCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research